Trial intelligence / Profile preview

DIAMOND Trial: DIAG723 in Hereditary Hemorrhagic Telangiectasia

NCT07623525Phase 2Recruiting

Start: Jun 2026
Primary completion: Nov 2027
Countries: 3

Overview

Phase 2, randomised, double-blind trial in hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH) comparing DIAG723 with Placebo Comparator (2 arms). Primary endpoints: Incidence of Treatment-Emergent Adverse Events, Incidence of Serious Adverse Events and 4 more. Started Jun 2026; status: recruiting.

Drugs

DIAG723

Conditions

hereditary hemorrhagic telangiectasia (HHT)pulmonary arterial hypertension (PAH)

Beyond the preview

Go deeper on NCT07623525.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT07623525.